Credit Suisse’s BioLineRX BLRX Stock Holding History

Credit Suisse’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-51	Closed	-$33K	–	3872
2018 Q3	$33K	Buy	+51	New	+$28.1K	﹤0.01%	3750
2013 Q3	–	Sell	-26	Closed	-$25K	–	4205
2013 Q2	$25K	Buy	+26	New	+$26.9K	﹤0.01%	4137

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

Susquehanna International Group

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Credit Suisse's BLRX Position: Q4 2018 in Review

Credit Suisse sold out of BioLineRX (BLRX) in Q4 2018, closing a stake of 51 shares — an estimated $33K sold.

Credit Suisse first reported a position in BLRX in Q2 2013 and held it in 2 quarters. The position peaked at $33K in Q3 2018. 34 funds tracked by Wall St. Rank hold BLRX as of Q4 2018.

Credit Suisse reported no remaining BioLineRX position as of Q4 2018 after selling out during the quarter.
Credit Suisse sold 51 BioLineRX shares in Q4 2018, an estimated $33K.
Credit Suisse first reported a position in BioLineRX in Q2 2013 and held it in 2 quarters.
Credit Suisse's BioLineRX position peaked at $33K in Q3 2018.
34 funds tracked by Wall St. Rank held BioLineRX as of Q4 2018.

Based on Credit Suisse's 13F filing for Q4 2018, filed 13 Feb 2019.